English
Regional settings| Spread | 0.0562 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.0269 |
| Open | 0.9967 |
| 1-Year Change | -35.22% |
| Day's Range | 0.9967 - 1.0469 |
Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.
BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).
